Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 10579.145 | 0.8774 | 0.7691 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 10579.145 | 0.9434 | 0.8937 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 10579.145 | 0.9232 | 0.8556 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 10579.145 | 0.7751 | 0.5750 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 4 | uM | 10579.145 | 0.5645 | 0.1700 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 20 | uM | 10579.145 | 0.5041 | 0.0521 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10579.145 | 0.4445 | -0.0649 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 12098.145 | 0.8607 | 0.7153 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 12098.145 | 0.9965 | 0.9929 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 12098.145 | 0.9383 | 0.8738 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 12098.145 | 0.9423 | 0.8819 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 12098.145 | 0.9491 | 0.8959 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 12098.145 | 0.8408 | 0.6748 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 4 | uM | 12098.145 | 0.6170 | 0.2201 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 20 | uM | 12098.145 | 0.2872 | -0.4423 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 100 | uM | 12098.145 | 0.2875 | -0.4418 | 0.9769 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.000256 | uM | 11058.145 | 0.9497 | 0.9537 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.00128 | uM | 11058.145 | 1.0240 | 1.0217 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.0064 | uM | 11058.145 | 0.9481 | 0.9522 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.032 | uM | 11058.145 | 0.9378 | 0.9425 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.16 | uM | 11058.145 | 0.9085 | 0.9148 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 0.8 | uM | 11058.145 | 0.7135 | 0.7160 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 4 | uM | 11058.145 | 0.3206 | 0.1937 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 20 | uM | 11058.145 | 0.1131 | -0.2562 | 2.2039 | |
| SUM229PE | TNBC | - | Bosutinib | Src | nRTK | 100 | uM | 11058.145 | 0.0649 | -0.4219 | 2.2039 |